|
Showing 1 - 2 of
2 matches in All Departments
Multiple Myeloma remains an incurable malignancy. As the disease
progresses, it invariably becomes resistant to treatment and almost
all patients develop refractory disease. There are multiple
different types of targeted therapies and many of them are used in
combination at different stages of disease. Targeted therapies that
are approved to be used include Proteasome Inhibitors,
Immunomodulatory Drugs and Monoclonal Antibodies. Second and third
generations of these drugs are developed to overcome resistance and
they have unique mechanism of actions. Targeted therapies that are
undergoing clinical trials include CAR-T cells, bi-specific
antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2
inhibitors. This book will help to develop an understanding of
targeted therapies in Multiple Myeloma. Its goal is to provide a
unique review of the mechanism of action and resistance of the many
targeted therapies in Multiple Myeloma by leaders of the field. The
book will be useful for students in medical science, clinicians,
health professionals, scientists, pharmaceutical professionals,
drug developers, and policy makers. This book will provide an
insightful knowledge of the biology of Multiple Myeloma, the
mechanism of action and resistance of targeted therapies,
application of biomarkers and genomics and possible strategies in
overcoming resistance and future development.
Multiple Myeloma remains an incurable malignancy. As the disease
progresses, it invariably becomes resistant to treatment and almost
all patients develop refractory disease. There are multiple
different types of targeted therapies and many of them are used in
combination at different stages of disease. Targeted therapies that
are approved to be used include Proteasome Inhibitors,
Immunomodulatory Drugs and Monoclonal Antibodies. Second and third
generations of these drugs are developed to overcome resistance and
they have unique mechanism of actions. Targeted therapies that are
undergoing clinical trials include CAR-T cells, bi-specific
antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2
inhibitors. This book will help to develop an understanding of
targeted therapies in Multiple Myeloma. Its goal is to provide a
unique review of the mechanism of action and resistance of the many
targeted therapies in Multiple Myeloma by leaders of the field. The
book will be useful for students in medical science, clinicians,
health professionals, scientists, pharmaceutical professionals,
drug developers, and policy makers. This book will provide an
insightful knowledge of the biology of Multiple Myeloma, the
mechanism of action and resistance of targeted therapies,
application of biomarkers and genomics and possible strategies in
overcoming resistance and future development.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Hampstead
Diane Keaton, Brendan Gleeson, …
DVD
R66
Discovery Miles 660
|